Topics:
Gastrointestinal Cancers • Medical Oncology • Neuroendocrine Tumors • NCI-CCC Tumor Board Question • University of Wisconsin • NCI-CCC GI Tumor Board Question
For a metastatic neuroendocrine tumor patient who has experienced prolonged progression free survival, how would you approach surgical debulking?
Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusiasm for debulking procedures? How aggressively should a patient be debulked?
Answer from: Medical Oncologist at Academic Institution
This is a complicated answer (especially for me as a medical oncologist...). The main factors to consider are the tumor grade, tumor behavior, extent and location of metastases, patient's age and performance, and the location of the primary tumor. For a patient with a G1/G2 pancreatic or SB NET...
Sign in or Register to read more